SAN FRANCISCO — The first prospective international randomized controlled study focusing specifically on angina in patients with diabetes has shown that ranolazine (Ranexa, Gilead Sciences) is an ...
In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...
What exactly is optimal medical therapy (OMT) for angina relief? And how long should doctors prescribe it before proceeding to an invasive approach in symptomatic patients with stable ischemic heart ...
Please provide your email address to receive an email when new articles are posted on . There are drug-drug interactions between the COVID-19 treatment ritonavir/nirmatrelvir and various classes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback